EUVIMEDEUVIMED entdecken
Open Access

Comparison of Cardiac Amyloidosis Due to Wild-Type and V122I Transthyretin in Older Adults Referred to an Academic Medical Center

Raymond C Givens, Chris Russo, Philip Green, Mathew S Maurer

Aging Health · 2013-04 · 9 (2) · 229-235

DOI: 10.2217/ahe.13.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging Health, online erschienen am 04.04.2013. Verfasst von Raymond C Givens und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cardiovascular Research Laboratory for the Elderly, Center for Advanced Cardiac Care, Division of Cardiology, Columbia College of Physicians…. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: In the USA, transthyretin cardiac amyloidosis usually results from 'wild-type' transthyretin (senile cardiac amyloidosis [SCA]) or the V122I variant. PATIENTS & METHODS: We compared presentations and outcomes among SCA and V122I patients referred to the Center for Advanced Cardiac Care at Columbia University Medical Center (NY, USA) between 2001 and 2012. RESULTS: V122I patients were younger (mean: 71 years, standard deviation [SD]: 7) than SCA patients (mean: 77, SD: 6; p = 0.0002) and 96% were black compared with 3% of SCA patients (p < 0.0001). Average ejection fraction was lower among V122I patients (mean: 25% [SD: 12] vs mean: 47% [SD: 15]; p = 0.0001), as was mean cardiac index. Median time to death or orthotopic heart transplant was 36.4 months for V122I patients and 66.5 for SCA patients (p = 0.09). CONCLUSION: In this study of patients with transthyretin cardiac amyloidosis, V122I patients presented to a tertiary academic medical center at a younger age than SCA patients but had higher levels of cardiac dysfunction, despite genetic screening availability. There was a trend toward shorter time to orthotopic heart transplant or death among V122I patients. Whether this is a result of a different biologic progression or late diagnosis requires further study.

Schlagwörter

Stichwörter der Autor:innen

African–Americanamyloidosiselderlyheart failuretransthyretin

Autor:innen und Institutionen

  • Clinical Cardiovascular Research Laboratory for the Elderly, Center for Advanced Cardiac Care, Division of Cardiology, Columbia College of Physicians & Surgeons, 622 West 168th Street, PH 12-1291, NY, USA.

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS
  • National Institute on Aging

Zitieren

APA

Givens, R. C., Russo, C., Green, P., & Maurer, M. S. (2013). Comparison of Cardiac Amyloidosis Due to Wild-Type and V122I Transthyretin in Older Adults Referred to an Academic Medical Center. Aging Health, 9(2), 229-235. https://doi.org/10.2217/ahe.13.10

Vancouver

Givens RC, Russo C, Green P, Maurer MS. Comparison of Cardiac Amyloidosis Due to Wild-Type and V122I Transthyretin in Older Adults Referred to an Academic Medical Center. Aging Health. 2013;9(2):229-235. doi:10.2217/ahe.13.10

BibTeX
@article{Givens2013,
  author = {Givens, Raymond C and Russo, Chris and Green, Philip and Maurer, Mathew S},
  title = {Comparison of Cardiac Amyloidosis Due to Wild-Type and V122I Transthyretin in Older Adults Referred to an Academic Medical Center},
  journal = {Aging Health},
  year = {2013},
  volume = {9},
  number = {2},
  pages = {229--235},
  doi = {10.2217/ahe.13.10}
}
Kostenlos starten →